Gb Sciences Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Gb Sciences Inc (GBLX) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Gb Sciences Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 3M vs 1,543M combined for tracked competitors (0.2% combined share).
- Trending: Latest-quarter revenue run-rate is decelerating (-86.9% annualized vs trailing 12 months), vs decelerating (-4.6%) for its tracked peer group.
- Profitability: Its -103.2% net margin compares with -39.6% for the peer group.
- Peer revenue share: Gb Sciences Inc accounted for 0.0% of combined revenue among its tracked peer group.
- Peer differentiation: Revenue per employee of $0.06M compares with $0.30M for the peer group (0.2x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
GBLX Sales vs. its Competitors, Q3 2024
With a net margin of -103.21 %, Gb Sciences Inc reported lower profitability than its competitors (-39.61 %).
Gb Sciences Inc generated 0.03 % of the combined sales of its peer group.
Gb Sciences Inc vs. its Competitors, Q3 2024
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Gb Sciences Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Gb Sciences Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (1) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Gb Sciences Inc's competitor groups requires a Commercial License.
Gb Sciences Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Gb Sciences Inc | - | - | - | Yes |
| Competitors combined (8) | ||||
| High-Confidence Competitors (2) | - | - | - |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
GBLX Stock Performance relative to its Competitors
GBLX Stock Performance relative to High-Confidence Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Cronos Group Inc | 282.9% | Outperformed |
| 2 | Aurora Cannabis Inc | 282.9% | Outperformed |
| 3 | Axim Biotechnologies Inc | 282.9% | Outperformed |
| 4 | Canopy Growth Corporation | 282.9% | Outperformed |
| 5 | Corbus Pharmaceuticals Holdings Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Gb Sciences Inc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Publicly Traded Peers of Gb Sciences Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Gb Sciences Inc | 0.08 | 2.98 |
| Cronos Group Inc | 1,237.70 | 259.21 |
| Tilray Brands Inc | 433.90 | 914.63 |
| Canopy Growth Corporation | 383.63 | 367.40 |
| Corbus Pharmaceuticals Holdings Inc | 129.06 | 1.54 |
| Tvardi Therapeutics Inc | 12.15 | - |
| SUBTOTAL | 2,197.75 | 1,915.38 |
Sign in to see all competitors of Gb Sciences Inc.
Sources: Gb Sciences Inc's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Gb Sciences Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Gb Sciences Inc's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Zynerba Pharmaceuticals Inc | Named by the company | 85% |
| Corbus Pharmaceuticals Holdings Inc | Named by the company | 85% |
| Cara Therapeutics Inc | Named by the company | 85% |
| Revive Therapeutics | Named by the company | 85% |
| Axim Biotechnologies Inc | Named by the company | 85% |
| Tvardi Therapeutics Inc | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Gb Sciences Inc's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Gb Sciences Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Tilray Brands Inc | Distribution Business 33.05 % |
| Canopy Growth Corporation | Storz and Bickel 58.69 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Gb Sciences Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Gb Sciences Inc | 0 | 59,521 | -20,859 |
| Cronos Group Inc | 1,238 | 424,938 | 129,843 |
| Tilray Brands Inc | 434 | 254,418 | -29,251 |
| Canopy Growth Corporation | 384 | 325,706 | -156,339 |
| Corbus Pharmaceuticals Holdings Inc | 129 | 42,775 | -2,830,639 |
| Tvardi Therapeutics Inc | 12 | - | -2,561,333 |
| PEERS TOTAL | 2,198 | 297,372 | -68,940 |
Gb Sciences Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Cronos Group Inc | Canada 56.07 % |
| Tilray Brands Inc | EMEA 39.41 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Gb Sciences Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 113 companies in Gb Sciences Inc's industry classification, broader than the peer set above. Market cap in millions of $.Gb Sciences Inc ranks #0 of 113 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 785, indicating a unconcentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Shell Plc | 285,644 | 19.05 % |
| 2 | Totalenergies Se | 210,300 | 14.02 % |
| 3 | Canadian Natural Resources Limited | 103,976 | 6.93 % |
| 4 | Eni Spa | 94,508 | 6.30 % |
| 5 | Slb Limited | 1,234 | 5.2% |
| 6 | Eog Resources Inc | 1,234 | 5.2% |
| 7 | Occidental Petroleum Corporation | 1,234 | 5.2% |
| 8 | Cenovus Energy Inc | 1,234 | 5.2% |
| 9 | Diamondback Energy Inc | 1,234 | 5.2% |
| 10 | Devon Energy Corp | 1,234 | 5.2% |
| 0 | Gb Sciences Inc | 0 | 0.00 % |
Market cap and industry share for the rest of Gb Sciences Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-09-28.
Gb Sciences Inc's Valuation vs Competitive Position
Valuation multiples vs the Oil And Gas Production industry average (165 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Oil And Gas Production industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 15.8x | - |
| EV / EBITDA | - | 8.9x | - |
| P/B | -0.2x | 1.8x | -2.0x |
| Return on Equity | 18.49 % | industry aggregate | 6.77 % |
| Return on Invested Capital | 7.80 % | 5.38 % (avg) | 2.42 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Gb Sciences Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | - | - | - | - | - | - | - | - |
| Operating Margin | - | -420.45 % | -387.46 % | - | - | - | - | - |
| Return on Invested Capital | -84.97 % | -32.22 % | -24.27 % | -613.93 % | -214.97 % | 51.06 % | 17.05 % | 7.80 % |
| P/E | - | - | - | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Gb Sciences Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 785 (see Industry Market Structure & Concentration above) |
| Supplier Power | Not covered on this page | See Gb Sciences Inc's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Gb Sciences Inc's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Gb Sciences Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Return on equity 6.8 points above the industry aggregate.
Weaknesses
- Latest-quarter revenue run-rate is decelerating (-86.9% annualized vs trailing 12 months).
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
No rule matched.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-4.6% annualized).
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Gb Sciences Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Gb Sciences Inc | 0.00 | 0.02 | - |
| Cronos Group Inc | 15.24 | 19.71 | - |
| Tilray Brands Inc | 0.83 | 2.49 | 0.22 |
| Canopy Growth Corporation | 2.01 | 3.43 | 0.42 |
| Corbus Pharmaceuticals Holdings Inc | 1.35 | 6.99 | - |
| Tvardi Therapeutics Inc | 2.19 | 2.65 | - |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Gb Sciences Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Gb Sciences Inc | Q4 2024 | - | - |
| Cronos Group Inc | Q2 2026 | +269.5 % | - |
| Tilray Brands Inc | Q2 2026 | +24.9 % | - |
| Canopy Growth Corporation | Q2 2026 | +12.9 % | - |
| Corbus Pharmaceuticals Holdings Inc | Q2 2026 | - | - |
| Tvardi Therapeutics Inc | Q2 2026 | - | - |
| PEERS TOTAL | +45.6 % | - |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Gb Sciences Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Gb Sciences Inc | Q4 2024 | - | - |
| Cronos Group Inc | Q2 2026 | +66.5 % | -80.8 % |
| Tilray Brands Inc | Q2 2026 | +21.0 % | - |
| Canopy Growth Corporation | Q2 2026 | +8.9 % | -50.5 % |
| Corbus Pharmaceuticals Holdings Inc | Q2 2026 | - | - |
| Tvardi Therapeutics Inc | Q2 2026 | - | - |
Gb Sciences Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Gb Sciences Inc | - | - | - |
| Cronos Group Inc | 6.70% | 6.90% | 7.25% |
| Tilray Brands Inc | - | - | - |
| Canopy Growth Corporation | - | - | - |
| Corbus Pharmaceuticals Holdings Inc | - | - | - |
| Tvardi Therapeutics Inc | - | - | - |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Gb Sciences Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Gb Sciences Inc | - | 0.03 |
| Cronos Group Inc | 15.71 | 4.77 |
| Tilray Brands Inc | - | 0.47 |
| Canopy Growth Corporation | - | 1.04 |
| Corbus Pharmaceuticals Holdings Inc | - | 83.81 |
| Tvardi Therapeutics Inc | - | - |
| PEERS AVERAGE | - | 1.15 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.